Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...2829303132333435363738...123124»
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Enrollment closed, Tumor mutational burden, IO biomarker, Metastases:  JS001-027-III-HCC: Phase III Study of Toripalimab?JS001? Combined With Lenvatinib for Advanced HCC (clinicaltrials.gov) -  Jul 20, 2023   
    P3,  N=530, Active, not recruiting, 
    Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025 Recruiting --> Active, not recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma. (Pubmed Central) -  Jul 20, 2023   
    To elucidate lenvatinib-induced molecular modulation, we performed bulk RNA-sequencing and digital spatial profiling of 5 surgically resected human HCC specimens after lenvatinib treatment and 10 matched controls without any preceding therapy. Besides its direct antitumor effects, lenvatinib recruited cytotoxic GZMK+CD8 T cells in intratumor stroma by CXCL9 from tumor-associated macrophages, suggesting that lenvatinib-treated HCC is in the so-called excluded condition that can diminish ICI efficacy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, Metastases:  Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. (Pubmed Central) -  Jul 17, 2023   
    The molecular mechanisms of lenvatinib resistance in patients with aHCC include the regulation of signaling pathways, the regulation of noncoding RNAs, the impact of the immune microenvironment, tumor stem cell activation and other mechanisms. This review aims to (1) summarize the progress of lenvatinib in treating aHCC, (2) delineate the known lenvatinib resistance mechanisms of current therapy, and (3) describe the development of therapeutic methods intended to overcome these resistance mechanisms.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal:  Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. (Pubmed Central) -  Jul 17, 2023   
    Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma. (Pubmed Central) -  Jul 12, 2023   
    Online data analysis of LR cells showed significant differences in the immune microenvironment and drug sensitivity compared with their parental counterparts. Taken together, AKR1C1 may serve as a candidate therapeutic target for LR liver cancer patients.
  • ||||||||||  Review, Journal:  Kinase inhibitors in thyroid cancers. (Pubmed Central) -  Jul 12, 2023   
    Dabrafenib plus trametinib for BRAF mutated anaplastic thyroid cancer provides an effective treatment option for this aggressive cancer with a dismal prognosis. In order to design the next generation of agents for thyroid cancer, future efforts will need to focus on developing a better understanding of the mechanisms of resistance to kinase inhibition including bypass signaling and escape mutations.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer. (Pubmed Central) -  Jul 11, 2023   
    The key to promoting the development of EC immunotherapy is to select the best patients according to the molecular classification and immunophenotype such as tumor mutation load, MMR status, pd-l1 expression, tumor infiltrating immune cells to truly achieve accurate and personalized treatment. More new and influential EC immunotherapies, such as adoptive cell immunotherapy, still need to be explored in future clinical practice.
  • ||||||||||  nofazinlimab (CS1003) / CStone Pharma
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  CS1003-305: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Jul 10, 2023   
    P3,  N=534, Active, not recruiting, 
    The design of the phase 2b study combines CMN-001 with first-line checkpoint inhibition therapy and second line lenvatinib/everolimus in poor-risk mRCC subjects. Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2023 --> Jun 2025
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, Metastases:  Metastatic Translocated Renal Cell Carcinoma in a Kidney Transplant Patient - a Case Report and Review of the Literature. (Pubmed Central) -  Jul 7, 2023   
    The primary tumour occurred in the native kidney and only focally showed biphasic morphology whereas the metastasis, among others to the transplant kidney, showed nonspecific, albeit different morphology, but both had consistent TFEB translocation. Treatment with the immune checkpoint inhibitor pembrolizumab together with the multi-kinase inhibitor lenvatinib achieved partial response 14 months after diagnosis.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC (clinicaltrials.gov) -  Jul 3, 2023   
    P4,  N=50, Recruiting, 
    To the best of our knowledge, this is the first case report of tracheoesophageal fistula at a nonmetastatic site during lenvatinib treatment for hepatocellular carcinoma. Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies. (Pubmed Central) -  Jul 2, 2023   
    Considering systemic therapies, the currently available tyrosine kinase inhibitors (sorafenib, regorafenib, cabozantinib and lenvatinib) and monoclonal antibodies (ramucirumab and bevacizumab, in combination with the anti-PD-L1, atezolizumab) primarily target, among others, angiogenic pathways. Considering the importance of angiogenesis in the pathogenesis and treatment of liver cancer, in this paper, we aim to review the role of angiogenesis in HCC, addressing the molecular mechanisms, available antiangiogenic therapies and prognostic biomarkers in patients receiving these treatments.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014-2022). (Pubmed Central) -  Jun 30, 2023   
    This scientometric and visual analysis provides a comprehensive summary of the published articles on lenvatinib in HCC during 2014-2022, highlighting the research hotspots, knowledge domain, and frontiers. The results can provide insights into future research directions in this field.